Evidence map›Paper›PMID 33512434›Full record

ArticleBlood2021

Nras Q61R/+ and Kras-/- cooperate to downregulate Rasgrp1 and promote lympho-myeloid leukemia in early T-cell precursors.

Zhi Wen, Grant Yun, Alexander Hebert, Guangyao Kong, Erik A Ranheim, Remington Finn, Adhithi Rajagoplan, Shuyi Li, Yun Zhou, Mei Yu and 6 more

Open access · greenAbstract read
In one paragraph

Article in Blood, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Zhi WenMcArdle Laboratory for Cancer Research.
Grant YunMcArdle Laboratory for Cancer Research.
Alexander HebertNational Center for Quantitative Biology of Complex Systems, University of Wisconsin-Madison, Madison, WI.
Guangyao KongMcArdle Laboratory for Cancer Research.ORCID 0000-0001-6662-0016
Erik A RanheimDepartment of Pathology & Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin Carbone Cancer Center, Madison, WI.
Remington FinnMcArdle Laboratory for Cancer Research.
Adhithi RajagoplanMcArdle Laboratory for Cancer Research.
Shuyi LiMcArdle Laboratory for Cancer Research.
Yun ZhouMcArdle Laboratory for Cancer Research.
Mei YuBlood Research Institute, Versiti, Milwaukee, WI.
Alisa DamnernsawadMcArdle Laboratory for Cancer Research.
Jeroen P RooseDepartment of Anatomy, University of California-San Francisco, San Francisco, CA; and.ORCID 0000-0003-4746-2811
Joshua J CoonNational Center for Quantitative Biology of Complex Systems, University of Wisconsin-Madison, Madison, WI.
Renren WenBlood Research Institute, Versiti, Milwaukee, WI.
Demin WangBlood Research Institute, Versiti, Milwaukee, WI.
Jing ZhangMcArdle Laboratory for Cancer Research.
Center for Cancer Research · USUniversity of Wisconsin–Madison · USVersiti Blood Center of Wisconsin · USUniversity of California, San Francisco · USUniversity of Wisconsin Carbone Cancer Center · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6M
TR&D 2 Metabolic Labels for Ultraplexed Protein Quantification p. 453P41GM108538 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI COON, JOSHUA J · 2016 to 2025
$13.1M
The role of TCOF1 in germline predisposition to and in leukemic transformation of chronic myelomonocytic leukemiaR01CA152108 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Jing Zhang · 2011 to 2026
$5.4M
B cell responses in heparin-induced thrombocytopeniaR01HL130724 · NHLBI · VERSITI WISCONSIN, INC. · PI WANG, DEMIN · 2017 to 2024
$4.8M
PLC?s in B cell biology and autoimmunityR01AI079087 · NIAID · VERSITI WISCONSIN, INC. · PI WANG, DEMIN · 2008 to 2018
$4.4M
Molecular Basis of the Humoral Immune Response in Heparin-Induced ThrombocytopeniaR01HL148120 · NHLBI · VERSITI WISCONSIN, INC. · PI Renren Wen · 2019 to 2026
$3.8M
Balanced signaling cues to guide cell transitions in the blood lineage continuumR01HL120724 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHAKRABORTY, ARUP K., NOLAN, GARRY P · 2015 to 2019
$3.7M
Molecular understanding of leukemic bone marrow cytokine-Ras signals and metabolic dependenceR01CA187318 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JEROEN ROOSE · 2015 to 2026
$3.6M
NCI NIH HHS P30 CA014520NCI NIH HHS R01 CA152108NCI NIH HHS R01 CA187318NHLBI NIH HHS R01 HL120724NHLBI NIH HHS R01 HL130724NHLBI NIH HHS R01 HL148120NIAID NIH HHS R01 AI079087NIGMS NIH HHS P41 GM108538
6 · The paper itself

Abstract

Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is an aggressive subtype of T-cell ALL. Although genetic mutations hyperactivating cytokine receptor/Ras signaling are prevalent in ETP-ALL, it remains unknown how activated Ras signaling contributes to ETP-ALL. Here, we find that in addition to the frequent oncogenic RAS mutations, wild-type (WT) KRAS transcript level was significantly downregulated in human ETP-ALL cells. Similarly, loss of WT Kras in NrasQ61R/+ mice promoted hyperactivation of extracellular signal-regulated kinase (ERK) signaling, thymocyte hyperproliferation, and expansion of the ETP compartment. Kras-/-; NrasQ61R/+ mice developed early onset of T-cell malignancy that recapitulates many biological and molecular features of human ETP-ALL. Mechanistically, RNA-sequencing analysis and quantitative proteomics study identified that Rasgrp1, a Ras guanine nucleotide exchange factor, was greatly downregulated in mouse and human ETP-ALL. Unexpectedly, hyperactivated Nras/ERK signaling suppressed Rasgrp1 expression and reduced Rasgrp1 level led to increased ERK signaling, thereby establishing a positive feedback loop to augment Nras/ERK signaling and promote cell proliferation. Corroborating our cell line data, Rasgrp1 haploinsufficiency induced Rasgrp1 downregulation and increased phosphorylated ERK level and ETP expansion in NrasQ61R/+ mice. Our study identifies Rasgrp1 as a negative regulator of Ras/ERK signaling in oncogenic Nras-driven ETP-like leukemia.

Indexed as

Down-RegulationGene Expression Regulation, LeukemicGuanine Nucleotide Exchange FactorsMonomeric GTP-Binding ProteinsMutation, MissensePrecursor T-Cell Lymphoblastic Leukemia-LymphomaAmino Acid SubstitutionAnimalsCell ProliferationHumansMAP Kinase Signaling SystemMiceMice, KnockoutProto-Oncogene Proteins p21(ras)Guanine Nucleotide Exchange FactorsHras protein, mouseMonomeric GTP-Binding ProteinsNras protein, mouseProto-Oncogene Proteins p21(ras)Rasgrp1 protein, mouseETP-like ALLKrasNEOPLASIA/lymphoid leukemiasNEOPLASIA/oncogene and anti-oncogene functiononcogenic NrasproteomicsRasgrp1

Identifiers

PMID33512434
PMCPMC8351901
OpenAlexW3123794944

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.